HDAC9 and plasma cell myeloma: Despite approval for T‐cell lymphoma and multiple myeloma, targeting histone deacetylase (HDAC) is a novel treatment for various malignancies and has been explored in phase II/III clinical trials.18 HDAC inhibitors have been demonstrated to inhibit tumour growth, induce cell cycle arrest and promote cell apoptosis.